



Chemotherapy for Primary Liver Cancer: Recent Updates and Future Perspectives

Guest Editor:

Dr. Etsushi Kawamura

Department of Hepatology,
Osaka Metropolitan University
Graduate School of Medicine, 1-
4-3 Asahimachi, Abeno-ku, Osaka
545-8585, Japan

Deadline for manuscript
submissions:

20 May 2024

Message from the Guest Editor

Dear Colleagues,

Worldwide, primary liver cancer is the sixth most common type of cancer and the third most common cause of death, with hepatocellular carcinoma (HCC) accounting for approximately 80% and intrahepatic cholangiocarcinoma (CC) approximately 15% of histological types.

Treatment options for HCC and intrahepatic CC have increased, and long-term survival has been achieved. On the other hand, countermeasures against immune-related adverse events have become necessary. We expect to further improve therapeutic outcomes by understanding that hepatocellular carcinoma has a variety of cellular origins and tumor microenvironments.

We invite you to contribute to this Special Issue on "Chemotherapy of Primary Liver Cancer". Original research articles and reviews are welcome in this Special Issue. Areas of research may include (but are not limited to) the following:

- Diagnosis of chemotherapy efficacy (including biomarkers and imaging techniques);
- Combination of locoregional therapy (transcatheter arterial chemoembolization or hepatic arterial infusion chemotherapy) and systemic drug therapy.

I look forward to receiving your contributions.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI